Background-Preterm (PT) infants are at greater risk for severe influenza infection and experience decrements in long-term antibody responses to vaccines. This may related to defects in antibody secreting cell (ASC) generation.
Introduction
Infants, particularly preterm (PT) infants, are at a greater risk for severe influenza infection and related complications [1] . PT infants are born with immature immune systems, including defects in B-cell function, yet it is unclear how prematurity affects the quality of the cellular vaccine responses or when immune function matures after birth [2] . Compared to full term (FT) infants, extremely PT infants have decrements in serum titers to a number of vaccines that can persist at least to school age [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Although PT and FT infants exhibit similar acute serological responses to influenza vaccines [19] , no studies have assessed long term immunogenicity or cellular immunity following influenza vaccine among PT infants.
After vaccination, protective antibody titers originate from naïve B cell differentiation into antibody secreting cells (ASC) and memory B cells in infants. In adults, most circulating ASC demonstrate vaccine antigen specificity with little bystander response [20] , and influenza-specific ASC frequency correlates with the rise in protective antibody titers [21] . Among adults, there is significant heterogeneity in the ASC (CD19 + CD27 hi CD38 hi ) subsets after vaccination that include CD138 + and CD138 neg subsets [22, 23] . We have also identified CD19 neg ASC populations after vaccination that resemble a recently described human bone marrow long-lived plasma cell (LLPC) phenotype by cell surface markers [24] .
We evaluated the relationships among the frequencies of influenza-specific antibody secreting cells ASC numbers and subsets and antibody responses to influenza vaccines (IV) among PT and full-term (FT) infants.
Materials and Methods

Subjects
In this prospective study, infants were recruited during the 2012-2013 and 2013-2014 influenza vaccine seasons at the University of Rochester. We enrolled very-low-birth-weight (≤ 1500 grams at birth), PT (≤ 32 weeks' gestation at birth) infants and normal-birth-weight (> 2500 grams at birth), FT (35 0/7 to 41 6/7 weeks' gestation at birth) infants into the study. Subjects were 6-17 months chronological age, previously un-immunized for influenza, and eligible for influenza immunization. Subjects with known immunodeficiency, concurrent systemic corticosteroid administration or physician-diagnosed influenza illness were excluded. The Institutional Review Board approved the study, and informed parental permission was obtained.
Children had six study visits over 9 months, at 0 (Visit 1), 10 (Visit 2), 28 (Visit 3), 35 (Visit 4) and 56 (Visit 5) days, and 9 months (Vsiit 6) from the first dose of influenza vaccine ( Figure 1 ). Children received two doses (prime/boost) by intramuscular thigh injection with a 1-inch needle of trivalent (TIV) (H1N1, H3N2, B-Yamagata, 2012-2013 season, multiple lots) or quadrivalent (QIV) (H1N1, H3N2 Figure 1 ). An interim medical history, focused on influenza symptoms, was obtained at each study visit.
Peripheral blood mononuclear cell (PBMC) isolation
PBMC were isolated as previously described [25] . Briefly, plasma was first separated by centrifugation at room temperature. The blood, diluted 1:2 with phosphate buffered saline was centrifuged over a Ficoll gradient. The buffy coat layer was transferred to a 15-mL tube, and the cells were washed with HBSS. Cells were counted and viability assessed by Trypan Blue exclusion. All enzyme-linked immunospot (ELISPOT) and flow cytometry assays were done on fresh cells.
Influenza hemagglutination inhibition assay (HAI)
Sera were separated and frozen at −80°C until analysis. Influenza antibody levels were measured by microtiter hemagglutination inhibition (HAI) test, as previously described [19] . Briefly, reagents for the HAI test were obtained from the WHO Collaborating Centers for Influenza, Centers for Disease Control and Prevention. Hemagglutination titer for each influenza antigen was determined and diluted to contain 4 HA units in 0.025-mL of virus suspension. H1N1, H3N2, B/Victoria, and B/Yamagata antigens were used. Serum titers were determined by the highest dilution of serum capable of inhibiting hemagglutination. A serum control was run on each plate, and all assays within a vaccine season were run using the same lot of antigen.
Antigen-specific ASC ELISPOT
The frequency of influenza antigen-specific ASCs was measured by ELISPOT, as previously described [21] . Briefly, 96-well ELISPOT plates were coated for 2 hours at room temperature with the following: TIV for the 2012-2013 cohort (6 μg/mL, Sanofi Pasteur), QIV for the 2013-2014 cohort (8 μg/mL, Sanofi Pasteur), goat anti-human IgG (5 μg/mL, Invitrogen), tetanus toxoid (2 μg/ml, Calbiochem) or Bovine Serum Albumin (2% in PBS, Fisher), diluted in PBS. Plates were then washed and blocked with RPMI + fetal bovine serum + antibiotic/antimycotic for 2 hours at 37°C with 5% CO 2 . Plates were incubated at 37°C with 8% CO2 for 18-20 hours with 300,000, 100,000 or 10,000 PBMC in duplicate. Cells were then aspirated and plates washed with PBS with 0.1% Tween. Bound antibodies were detected with alkaline phosphatase-conjugated goat-anti-human IgG (1 μg/mL, Jackson Immunoresearch) for 2 hours and washed with PBS/Tween. Plates were developed with Vector Alkaline Phosphatase Substrate Kit III. Spots in each well were counted using a CTL Immunospot reader.
Polychromatic flow cytometry
An aliquot of PBMC were stained with anti-human Ki67-FITC, IgD-PE, CD20-Cy5PE, CD3/CD14-Cy5.5PE, CD19-Cy7PE, CD38-V450 (PacBlue), CD138-APC, and CD27-APCeFluor780 and analyzed by flow cytometry (LSR II, Biosciences, Franklin Lakes, NJ) using FlowJo software (Tree Star, Inc., Ashland, OR) as previously described [24] .
Statistical analysis
All statistical analyses were performed using SAS (version 9.4, SAS Institute Inc, Cary, NC). The Fisher's exact test was used for categorical variables while t-test or Wilcoxon Rank Sum test was used for continuous variables. HAI titers were log-transformed to satisfy the normality assumption of the models. Spearman correlation coefficient (ρ) was used to evaluate the correlation between outcome variables such as change in HAI titers, ASC frequencies measured by ELISPOT and ASC subset cells. HAI titers measured at different time points were also compared between study groups using repeated measure Analysis of Covariance (ANCOVA) after controlling for subject gender, baseline weight and age. Since the data were collected from two vaccine seasons, the potential batch effect of vaccines was examined by including the interaction with season. The association between the ASC subset cell populations and the change in HAI titers was also investigated using ANCOVA. All analyses were 2-sided at the 0.05 level of significance.
Results
Over two years, 11 premature infants (7 in 2012-2013, 4 in 2013-2014) and 11 full-term infants (3 in 2012-2013, 8 in 2013-2014) were enrolled. No infant was reported to have an influenza-like illness either before or during the study. However, one full-term subject from the 2012-2013 season was excluded from analyses due to serological evidence of prior B/ Victoria influenza infection. All PT infants and 8 FT infants completed all visits, but small volumes from blood draws limited the sample available for some analyses. The denominator for each assay is given in the appropriate Table or Figure. Subject characteristics are shown in Table 1 . PT infants were of similar postnatal age, but weighed less, than FT infants. The time between the first and second doses of vaccine was similar between the two groups. No infant suffered a vaccine-related or study-related adverse event.
When HAI geometric mean titers (GMT) for H3N2 and B/Yamagata were higher in PT than FT children at one month after the boost (Visit 5) ( Figure 2A ). There were no differences between groups children reaching nominal protective antibody titers of either 1:32 or 1:64, other than a difference in B/Yamagata titers ≥1:64 favoring PT infants at Visit 5 ( 
Author Manuscript
Author Manuscript
Author Manuscript [26] . PT infants had a larger fold change in antibody titer compared to FT infants following two vaccine doses for H3N2 and B/Yamagata, and a larger fall in titer of B/Yamagata and B/ Victoria from the peak titer (Visit 5) to 9 months (Visit 6) ( Figure 2B ).
Since we had previously shown that chronological age explained differences between PT and FT influenza HAI titers [19] , we performed secondary analyses for the HAI results controlling for age, weight and sex. When controlled for co-variates, the HAI titer GMT did not differ statistically significantly between PT and FT infants for any strain at any time. Evaluation also showed no effect of season on titer and no interaction of titer and season (p>0.25 for all analyses).
Representative ELISPOT wells from PT and FT infants are shown in Figure 3A . Quality and size of the spots did not differ significantly between the two groups. ASC ELISPOT frequencies were higher among PT than FT infants at Visit 4 (seven days after the second dose of vaccine) ( Figure 3B ). Additionally, ASC frequencies at Visit 4 correlated with HAI titers for all four strains at Visit 5 ( Figure 3C ). ASC frequencies at Visit 4 also correlated with individual antibody titer to the H1N1 (ρ = 0.60, p = 0.008) and B/Victoria (ρ = 0.65, p = 0.04) HAI titers at nine months (Visit 6).
Although mature long-lived plasma cells in the human bone marrow express high levels of CD138 and a fraction of the circulating ASC also can express CD138 in adults [24, 27] , little was known if ASC from both PT and FT infants can express CD138. We identified five distinct ASC subsets using CD19, CD38, and CD138 similar to markers used in human BM. Population (Pop) 1 cells were identified as CD19 + CD38 + CD138 neg and contains both B cells and early ASCs. Two CD19 + subsets included pop 2: CD19 + CD38 hi CD138 neg and pop 3: CD19 + CD38 h iCD138 + and two CD19 neg subsets included pop 4:CD19 neg CD38 hi CD138 neg and pop 5: CD19 neg CD38 hi CD138 + ( Figure 4A ). Both FT and PT infants expressed CD138 + ASC subsets (pop 3& 5) although the majority of ASC subsets after vaccination in both FT and PT was pop 2: CD19 + CD138 neg ( Figure 4B ). There were no differences in frequency of any ASC subset at any time between PT and FT infants.
Although the frequency of one ASC subset (pop 3: CD19 + CD38 hi CD138 + ) appeared higher among PT at the peak of the ASC responses (Visit 4), this difference did not reach statistical significance (p = 0.052). There was no correlation between the frequency of any ASC subset at the peak of the cellular ASC responses (Visit 4) and the rise in HAI titer for any strain one month after vaccination (data not shown) or the decay between the peak and at 9 months ( Figure 4C ).
Discussion
In this study, we validated similar influenza HAI titers in both PT and FT infants after the recommended initial influenza vaccine series. PT infants had higher peak HAI titers than FT infants to some vaccine antigens, and the peak serum titers correlated with the vaccinespecific ASC frequencies in all infants. There were few differences in the proportions of infants who reached protective titers, which are in any case only approximations of vaccine effectiveness [26, 28] . Both PT and FT infants had significant heterogeneity of the ASC subsets after the first influenza vaccine. By flow cytometry, we were able to identify 5 distinct ASC populations in the blood after vaccination, which are similar to findings in adults (unpublished data). This is among the first studies to demonstrate that heterogeneity of ASC subsets (both CD19 + and CD19 neg and CD138 + and CD138 neg subsets) occur in PT infants, suggesting that gestational age does not affect generation of heterogeneity of ASC subsets. We did not see a correlation between any particular ASC subset and durability of HAI titers.
The elevated humoral response of the PT infant group is consistent with our previous findings that PT infants had higher serum antibody titers than FT infants after immunization with influenza, MMR and varicella vaccines [19, 29] . Multivariate analysis showed that factors such as gender, weight and postnatal age explain some of the differences between FT and PT infant titers, a finding in keeping with our previous work [19] . PT infants had lower baseline HAI titers prior to vaccination, which may have been a result of limited placental transmission of maternal antibodies [30, 31] . Lower initial antibody titers may have limited antibody blocking of vaccine antigen, resulting in the higher rises of HAI titers and larger vaccine-specific ASC frequencies seen in the PT infants.
Human long-lived plasma cells (LLPC) are responsible for long-term maintenance of protective serum antibodies [32] [33] [34] , and our group has recently identified the human LLPC in the bone marrow by showing long-lived viral responses in only one (CD19 neg CD38 hi CD138 + ) plasma cell subset [24] . This LLPC compartment is morphologically and transcriptionally distinct compared to the short-lived bone marrow (BM) plasma cells, with distinct vacuoles, tighter chromatin and increased number of autophagosomes and a unique autophagy signature [24] . Although the goal of human vaccines is to generate and sustain LLPC, the mechanisms of how human LLPC formation are not well understood.
The presence of specific B cell populations in the blood of aged individuals has been correlated to poor vaccine responses to influenza, which may be due in part to altered T helper cell function [35, 36] . Furthermore, the CD4+ T cell response to Streptococcus pneumoniae and Haemophilus influenzae vaccines are lower in pediatric subjects than in adults [37] . This could be partially explained by differences in soluble factors that are found at different levels in childrens than in adults, including increased IL-10 and decreased TNFα [38, 39] . Thus, alterations in cellular phenotype may affect vaccine response in both aged individuals and children born preterm.
Distinct CD19 neg and CD138 + ASC subsets are found in the blood of adults after highly effective vaccines such as tetanus toxoid (with a 10-year antibody half life), suggesting that heterogeneity of ASC subsets are important for long-lived vaccine responses [22, 23] . To our surprise, all ASC subsets were found among very PT infants and, despite lack of correlation with ASC subsets, we were able to measure influenza HAI titers at 9 months after immunization.
In this study, despite the higher peak of serum antibodies, PT infants had a larger fall in antibody titer by 9 months post-vaccine than FT infants, resulting in similar HAI values among FT and PT infants at 9 months. These results suggest that PT infants may not generate LLPC as efficiently as FT infants to sustain protective antibody titers. However, ASC heterogeneity in subsets was similar between PT and FT infants suggesting extrinsic mechanistic differences beyond ASC may be responsible for persistence of plasma cell survival in the FT infants. One explanation could be differences in migratory capacity of ASC to BM survival niches, since CXCR4 has been shown to be important for LLPC generation [40] . Another difference could be an immature BM microenvironment in PT compared to FT infants, which could play a critical role plasma cell survival. More studies are needed with particular focus on understanding differences in BM microenvironments between PT and FT infants.
This study has several limitations. The sample size was small, giving limited power for the analyses and raising the possibility of missing small differences in ASC populations associated with antibody durability. The study population was drawn from two influenza vaccine seasons, with an imbalance of PT and FT infants between seasons. However, the three shared vaccine components (H1N1, H3N2 and B/Yamagata) were similar between seasons, and we previously found no differences between vaccine responses distributed over two seasons [19] . Further, additional analysis suggested no effect of season on the results. Despite attempts to rule out influenza virus exposure among enrollees, one infant showed serological evidence of prior influenza infection. Other infants could have had asymptomatic influenza infections during the study. Baseline titers allowed us to rule out pre-existing influenza exposure, but we could not completely rule out illness acquired during the study.
Although our study focused on influenza-IgG class-switched ASC, the HAI assay and ASC subsets evaluated all isotypes. Since antibody type and specificity mediate different downstream biological effects (e.g., antibody-dependent cell-mediated cytotoxity or interferance with intracellular uncoating of viral particles) [41, 42] , our study did not specifically address the potentially differential effects of various isotypes.
This study supports the suggestion that by 6 months of age, the immunological immaturity of vaccine responses displayed by PT infants at birth and thereafter has largely resolved [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . The similarity to FT infants in ASC numbers and ASC subpopulations provides further supporting evidence for the relative immunological maturity of 6-month-old former extremely PT infants. However, questions of protective antibody durability and LLPC generation in PT infants remain.
In conclusion, this study explored the relationship among antibody titers, influenza-specific ASC, and ASC subsets measured by flow cytometry in PT and FT infants. It was unique in the use of multiple comprehensive assessments at many time points over months. Influenza vaccination among premature infants produces strong and durable antibody responses and remains one of the most effective methods of preventing severe influenza and its complications among this vulnerable population.
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